CellProthera is a medical biotech company founded in 2008 in Mulhouse (France). Its activity is currently focused on the development of a revolutionary therapeutic approach allowing the regeneration of myocardial tissue following acute myocardial infarct by injection of a cell graft containing autologous adult stem cells (ASC) sampled directly from the patient.
CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits. The innovative approach developed by CellProthera is viewed by experts as one of the most effective to treat AMI and prevent secondary congestive heart failure (CHF). This “rupture” therapy has been assessed in a preliminary Proof of Concept clinical trial. This represents a unique alternative to cardiac transplant and can be a complement and/or a substitute for existing therapies like coronary bypass surgery and stenting.
The need is overwhelming, solving it our goal
CellProthera has earned very strong support from French authorities, public and private investors as illustrated by the various awards received.
Functional benefit after grafting autologous stem cell viewed through cardiac echography
CellProthera achieves a revolutionary breakthrough in the treatment of myocardial infarction,